Enhancing Injectable Drugs

  • We are a specialty pharmaceutical company focused on developing and commercializing injectable products,
    primarily in the critical care and oncology areas, using the 505(b)(2) regulatory pathway. Our goal is to enter the market before any generics with enhanced versions of existing injectable drugs.

  • Specialty Injectables

    Speciality pharmaceutical company focused on developing and commercializing products for hospital and outpatient infusion clinics.

  • High Value Portfolio of Assets

    Formulation technology and know-how, patent strategy, and market understanding drive product development and Eagle's ability to create value.

  • 13Feb

    License Agreement with Teva - Rapid Infusion Bendamustine

    License Agreement with Teva - Rapid Infusion Bendamustine

    Read More
  • 13Feb

    NDA Submitted - Rapid Infusion Bendamustine

    NDA Submitted - Rapid Infusion Bendamustine

    Read More
  • 23Feb

    Ryanodex® Granted ODD Market Exclusivity

    Ryanodex® Granted ODD Market Exclusivity

    Read More